Demystifying the diagnosis and management of ICUS, CHIP, and CCUS.

Abstract

Precursor states such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance, carry distinct risks for progression to myeloid neoplasms and age-related comorbidities. While biologically distinct, idiopathic cytopenia of undetermined significance is also a differential diagnostic consideration for these precursor lesions. Through 3 illustrative cases, we highlight the diagnostic complexity and clinical relevance of these entities, emphasizing the need for integrated clinical, morphologic, and molecular assessment to guide individualized patient care. Emerging evidence suggests that CHIP contributes not only to hematopoietic stem cell aberrations and potential myeloid neoplasia but also to cardiovascular disease and solid-tumor outcomes, reinforcing its significance as a systemic biomarker. We summarize the current risk stratification tools and ongoing clinical trials aimed at modulating inflammation and clonal dynamics in CH-associated conditions. We also outline our approach from our Clonal Hematopoiesis Clinic, which incorporates surveillance, preventive care, and clinical trial enrollment. Establishing standardized diagnostic criteria, harmonizing trial frameworks, and formally incorporating CHIP into hematology, oncology, cardiology, and survivorship paradigms will be essential to reducing long-term morbidity and improving patient outcomes.